INCYTE CORP (INCY)
US45337C1027 - Common Stock
INCY gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. INCY scores excellent points on both the profitability and health parts. This is a solid base for a good stock. INCY has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! With these ratings, INCY could be worth investigating further for value and growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year INCY was profitable.
In the past year INCY had a positive cash flow from operations.
Of the past 5 years INCY 4 years were profitable.
INCY had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of INCY (8.81%) is better than 96.92% of its industry peers.
INCY has a better Return On Equity (11.51%) than 96.58% of its industry peers.
INCY has a Return On Invested Capital of 8.00%. This is amongst the best in the industry. INCY outperforms 96.40% of its industry peers.
The Average Return On Invested Capital over the past 3 years for INCY is below the industry average of 13.58%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.81% | ||
| ROE | 11.51% | ||
| ROIC | 8% |
ROA(3y)11.29%
ROA(5y)7.72%
ROE(3y)14.82%
ROE(5y)10.07%
ROIC(3y)9.11%
ROIC(5y)N/A
1.3 Margins
INCY has a Profit Margin of 16.17%. This is amongst the best in the industry. INCY outperforms 97.09% of its industry peers.
In the last couple of years the Profit Margin of INCY has grown nicely.
The Operating Margin of INCY (17.64%) is better than 96.75% of its industry peers.
In the last couple of years the Operating Margin of INCY has grown nicely.
INCY has a better Gross Margin (93.71%) than 95.21% of its industry peers.
In the last couple of years the Gross Margin of INCY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.64% | ||
| PM (TTM) | 16.17% | ||
| GM | 93.71% |
OM growth 3YN/A
OM growth 5Y16.39%
PM growth 3YN/A
PM growth 5Y22.68%
GM growth 3Y-0.76%
GM growth 5Y-0.51%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so INCY is destroying value.
INCY has more shares outstanding than it did 1 year ago.
INCY has more shares outstanding than it did 5 years ago.
INCY has a better debt/assets ratio than last year.
2.2 Solvency
INCY has an Altman-Z score of 5.89. This indicates that INCY is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of INCY (5.89) is better than 82.19% of its industry peers.
The Debt to FCF ratio of INCY is 0.07, which is an excellent value as it means it would take INCY, only 0.07 years of fcf income to pay off all of its debts.
INCY has a better Debt to FCF ratio (0.07) than 97.60% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that INCY is not too dependend on debt financing.
INCY has a Debt to Equity ratio (0.01) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.07 | ||
| Altman-Z | 5.89 |
ROIC/WACC0.87
WACC9.24%
2.3 Liquidity
A Current Ratio of 3.75 indicates that INCY has no problem at all paying its short term obligations.
INCY has a Current ratio (3.75) which is in line with its industry peers.
INCY has a Quick Ratio of 3.69. This indicates that INCY is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.69, INCY perfoms like the industry average, outperforming 43.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.69 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 26.62% over the past year.
The Earnings Per Share has been growing by 27.86% on average over the past years. This is a very strong growth
Looking at the last year, INCY shows a quite strong growth in Revenue. The Revenue has grown by 8.87% in the last year.
INCY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.45% yearly.
EPS 1Y (TTM)26.62%
EPS 3YN/A
EPS 5Y27.86%
EPS growth Q2Q70.97%
Revenue 1Y (TTM)8.87%
Revenue growth 3Y11.49%
Revenue growth 5Y14.45%
Revenue growth Q2Q9.35%
3.2 Future
INCY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.66% yearly.
The Revenue is expected to grow by 8.13% on average over the next years. This is quite good.
EPS Next Y31.69%
EPS Next 2Y24.97%
EPS Next 3Y24.94%
EPS Next 5Y18.67%
Revenue Next Year12.46%
Revenue Next 2Y11.59%
Revenue Next 3Y11.38%
Revenue Next 5Y8.13%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 14.75, the valuation of INCY can be described as correct.
Compared to the rest of the industry, the Price/Earnings ratio of INCY indicates a rather cheap valuation: INCY is cheaper than 97.43% of the companies listed in the same industry.
INCY is valuated rather cheaply when we compare the Price/Earnings ratio to 24.95, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 11.20, the valuation of INCY can be described as reasonable.
INCY's Price/Forward Earnings ratio is rather cheap when compared to the industry. INCY is cheaper than 98.63% of the companies in the same industry.
INCY's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 21.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.75 | ||
| Fwd PE | 11.2 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, INCY is valued cheaper than 97.77% of the companies in the same industry.
96.23% of the companies in the same industry are more expensive than INCY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.12 | ||
| EV/EBITDA | 9.73 |
4.3 Compensation for Growth
INCY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of INCY may justify a higher PE ratio.
A more expensive valuation may be justified as INCY's earnings are expected to grow with 24.94% in the coming years.
PEG (NY)0.47
PEG (5Y)0.53
EPS Next 2Y24.97%
EPS Next 3Y24.94%
5. Dividend
5.1 Amount
No dividends for INCY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INCYTE CORP
NASDAQ:INCY (4/22/2024, 7:08:22 PM)
After market: 51.92 0 (0%)51.92
-0.43 (-0.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap11.66B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.75 | ||
| Fwd PE | 11.2 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.47
PEG (5Y)0.53
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.81% | ||
| ROE | 11.51% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 17.64% | ||
| PM (TTM) | 16.17% | ||
| GM | 93.71% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.75 | ||
| Quick Ratio | 3.69 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)26.62%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y31.69%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)8.87%
Revenue growth 3Y11.49%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y